Peter S Grimison

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. ncbi Primary pancreatic lymphoma--pancreatic tumours that are potentially curable without resection, a retrospective review of four cases
    Peter S Grimison
    Institute of Oncology, Prince of Wales Hospital, Sydney, Australia
    BMC Cancer 6:117. 2006
  2. ncbi Quality of life and adjuvant systemic therapy for early-stage breast cancer
    Peter S Grimison
    NHMRC Clinical Trials Centre, Building M02F, University of Sydney, NSW 2006, Australia
    Expert Rev Anticancer Ther 7:1123-34. 2007
  3. ncbi Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer
    Peter S Grimison
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
    Value Health 12:967-76. 2009
  4. ncbi Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial
    Peter S Grimison
    Sydney Cancer Centre, Gloucester House 6, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia
    J Natl Cancer Inst 102:1253-62. 2010
  5. ncbi Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer
    Martin R Stockler
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    J Clin Oncol 29:4498-504. 2011
  6. ncbi Deriving a patient-based utility index from a cancer-specific quality of life questionnaire
    Peter S Grimison
    NHMRC Clinical Trials Centre, University of Sydney, Australia
    Value Health 12:800-7. 2009

Detail Information

Publications6

  1. ncbi Primary pancreatic lymphoma--pancreatic tumours that are potentially curable without resection, a retrospective review of four cases
    Peter S Grimison
    Institute of Oncology, Prince of Wales Hospital, Sydney, Australia
    BMC Cancer 6:117. 2006
    ..Symptoms, imaging and tumour markers can mimic pancreatic adenocarcinoma, but they are much more amenable to treatment. Treatment for PPL remains controversial, particularly the role of surgical resection...
  2. ncbi Quality of life and adjuvant systemic therapy for early-stage breast cancer
    Peter S Grimison
    NHMRC Clinical Trials Centre, Building M02F, University of Sydney, NSW 2006, Australia
    Expert Rev Anticancer Ther 7:1123-34. 2007
    ..New technologies will make HRQL information increasingly available for individual patient care...
  3. ncbi Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer
    Peter S Grimison
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
    Value Health 12:967-76. 2009
    ..The index is designed to reflect the perspective of cancer patients in a specific clinical context so as to best inform clinical decisions...
  4. ncbi Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial
    Peter S Grimison
    Sydney Cancer Centre, Gloucester House 6, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia
    J Natl Cancer Inst 102:1253-62. 2010
    ..The aim of this analysis was to determine if this survival benefit was maintained with long-term follow-up...
  5. ncbi Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer
    Martin R Stockler
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    J Clin Oncol 29:4498-504. 2011
    ....
  6. ncbi Deriving a patient-based utility index from a cancer-specific quality of life questionnaire
    Peter S Grimison
    NHMRC Clinical Trials Centre, University of Sydney, Australia
    Value Health 12:800-7. 2009
    ....